Taysha Gene Therapies (NASDAQ:TSHA) Hits New 12-Month High – Here’s What Happened

Taysha Gene Therapies, Inc. (NASDAQ:TSHA)’s share price reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $6.81 and last traded at $6.6250, with a volume of 254924 shares traded. The stock had previously closed at $6.64.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Truist Financial upgraded shares of Taysha Gene Therapies to a “strong-buy” rating in a research report on Wednesday, March 25th. Wall Street Zen upgraded shares of Taysha Gene Therapies from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Needham & Company LLC raised their price objective on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, March 19th. Wells Fargo & Company raised their price objective on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, January 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Friday, March 27th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $11.64.

Taysha Gene Therapies Stock Performance

The firm’s 50 day moving average is $4.95 and its two-hundred day moving average is $4.89. The company has a debt-to-equity ratio of 0.20, a quick ratio of 12.23 and a current ratio of 12.23. The stock has a market capitalization of $1.92 billion, a PE ratio of -19.61 and a beta of 1.25.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings results on Thursday, March 19th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. The firm had revenue of $5.49 million during the quarter, compared to analysts’ expectations of $1.89 million. As a group, research analysts predict that Taysha Gene Therapies, Inc. will post -0.41 earnings per share for the current year.

Insider Transactions at Taysha Gene Therapies

In related news, insider Sukumar Nagendran sold 200,000 shares of the business’s stock in a transaction dated Friday, April 10th. The shares were sold at an average price of $4.46, for a total transaction of $892,000.00. Following the completion of the sale, the insider owned 1,136,410 shares of the company’s stock, valued at $5,068,388.60. This represents a 14.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.78% of the stock is owned by company insiders.

Institutional Trading of Taysha Gene Therapies

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Marex Group plc acquired a new position in Taysha Gene Therapies during the 2nd quarter valued at approximately $29,000. E Fund Management Co. Ltd. acquired a new position in Taysha Gene Therapies during the 2nd quarter valued at about $31,000. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in Taysha Gene Therapies during the 3rd quarter valued at about $40,000. Tower Research Capital LLC TRC boosted its stake in Taysha Gene Therapies by 156.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock valued at $41,000 after purchasing an additional 10,742 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its stake in Taysha Gene Therapies by 143.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock valued at $43,000 after purchasing an additional 4,607 shares during the period. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.